$MBOT

Microbot Medical Inc. (MBOT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0000883975 0000883975 2026-08-06 2026-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Microbot Medical (Nasdaq: MBOT) reported Q2 2026 revenue and new-customer growth of more than 100% vs Q1 2026, citing the LIBERTY System’s full market release on April 13. The company says procedure volumes rose at prior limited-release sites, expanded U.S. sales territories from 4 to 8 (target 12 by year-end), added a federal-services agreement, and received Israeli marketing clearance.

Microbot Medical Inc. has appointed Alon Tamir as Vice President of Sales for Europe, the Middle East, and Asia (EMEA) to accelerate commercial readiness in these international markets. This move follows the successful U.S. market release of its LIBERTY Endovascular Robotic System and aims to leverage the system's FDA clearance and anticipated CE mark approval by the end of 2026 for global expansion. Tamir will lead the EMEA sales strategy, focusing on go-to-market strategies, distribution, and strategic partnerships, seeing significant growth opportunities comparable to the U.S. market.

Microbot Medical (Nasdaq: MBOT) has appointed Alon Tamir as Vice President of Sales for EMEA to spearhead the commercialization of its LIBERTY Endovascular Robotic System in Europe, the Middle East, and Asia. The company, which gained FDA clearance in September 2025 and completed its U.S. market release, expects CE mark approval by the end of 2026, targeting Europe's estimated 2.3 million peripheral endovascular procedures. This strategic hire aims to establish regulatory, operational, and commercial capabilities to capitalize on significant international growth opportunities.

Microbot Medical Inc. filed a Form 424B5 prospectus supplement to offer and sell up to $39,230,691 of common stock through H.C. Wainwright & Co. as its sales agent. The company plans to use the net proceeds for the continued development, commercialization, and regulatory activities for its LIBERTY Robotic System, expansion of its intellectual property portfolio, potential acquisitions, and general corporate purposes. This offering is subject to various risk factors detailed in the document, including potential dilution for new investors.

Microbot Medical (NASDAQ:MBOT) is scheduled to release its earnings report before market open on Tuesday, March 24th, with analysts projecting an EPS of ($0.06) and revenue of $0.113 million. The stock currently has a "Moderate Buy" rating with an average target price of $7.50, and institutional investors have recently adjusted their stakes in the company. MBOT opened at $2.73, with a market cap of $183.35 million.

HINGHAM, Mass., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Microbot Medical Inc. ( Nasdaq: MBOT ) , developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University Hospital, a nationally recognized academic medical center in Atlanta, has become the first ...

Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Livestream Interview Can be Viewed on September 24th at 10:45am ET at Benzinga All Access Live Livestream Interview Can be Viewed on September 24th at 10:45am ET at Benzinga All Access Live ...

HINGHAM, Mass., Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Microbot Medical Inc. MBOT, developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, announces that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga All Access at 10:45am ET on Wednesday, ...